

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended)      A pharmaceutical composition comprising an electrospun fiber of a pharmaceutically acceptable amorphous polymeric carrier homogeneously integrated with a stable amorphous form of a pharmaceutically acceptable active agent.
2. (Cancelled)
3. (Previously presented)      The composition according to Claim 1 wherein the active agent is nanoparticle in size.
4. (Previously presented)      The composition according to Claim 1 wherein the active agent is water soluble.
5. (Previously presented)      The composition according to Claim 1 wherein the active agent is water insoluble.
6. (Original)      The composition according to Claim 1 wherein the active agent is sparingly water soluble.
7. (Previously presented)      The composition according to Claim 1 wherein the polymeric carrier is water soluble.
8. (Previously presented)      The composition according to Claim 1 wherein the polymeric carrier is water insoluble.
9. (Previously presented)      The composition according to Claim 1 wherein the composition further comprises a surfactant which is a block copolymer of ethylene oxide and propylene oxide, lecithin, sodium dioctyl sulfosuccinate, sodium lauryl sulfate, Polysorbate 20, 60 & 80, Sorbitan esters, Sorbitan Fatty Acids, Triton X-200, polyethylene glycol, glyceryl monostearate, d-alpha-tocopheryl polyethylene glycol 1000

succinate, sucrose fatty acid esters sucrose stearate, sucrose oleate, sucrose palmitate, sucrose laurate, sucrose acetate butyrate, or mixtures thereof.

10. (Original) The composition according to Claim 9 wherein the surfactant is present in an amount of 0 to about 15% w/w.

11. (Previously presented) The composition according to Claim 1 wherein the composition further comprises an absorption enhancer.

12. (Original) The composition according to Claim 1 which provides a taste masking effect of the active agent.

13. (Currently amended) The composition according to Claim 1 wherein the polymeric carrier is polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrrolidone, hyaluronic acid, alginates, carragenen, ~~cellulose derivatives such as~~ carboxymethyl cellulose sodium, ~~methyl cellulose, ethyl cellulose,~~ hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, ~~noncrystalline cellulose, starch and its derivatives such as~~ hydroxyethyl starch, sodium starch glycolate, ~~chitosan and its derivatives,~~ albumen, gelatin, collagen, polyacrylates and its derivatives, ~~poly(alpha-hydroxy acids),~~ poly(alpha-aminoacids) and its copolymers, poly(orthoesters), polyphosphazenes, or poly(phosphoesters).

14. (Original) The composition according to Claim 13 wherein the polymeric carrier is polyvinyl pyrrolidone or polyvinylpyrrolidone-co-polyvinylacetate.

15. (Previously presented) The composition according to Claim 13 wherein the polymeric carrier is Eudragit L100-55, Eudragit L30 D55, Eudragit L100, Eudragit S 100, Eudragit E 100, Eudragit EPO, Eudragit RL 30D, Eudragit RL PO, Eudragit RL 100, Eudragit RS 30D, Eudragit RS PO, Eudragit RS 100, Eudragit NE 30, or Eudragit NE 40, or a mixture thereof.

16. (Original) The composition according to Claim 1 wherein said drug substance is an analgesic, anti-inflammatory agent, anthelmintic, anti-arrhythmic agent, an antibiotic, anticoagulant, antidepressant, antidiabetic agent, antiepileptic, antihistamine, antihypertensive agent, antimuscarinic agent, antimycobacterial agent, antineoplastic

agent, immunosuppressant, antithyroid agent, antiviral agent, anxiolytic sedative, astringent, beta-adrenoceptor blocking agent, contrast media, corticosteroid, cough suppressant, diuretic, dopaminergic, homeostatic, immunological agent, lipid regulating agent, muscle relaxant, parasympathomimetic, parathyroid, calcitonin, prostaglandin, radio-pharmaceutical, sex hormone, steroid, anti-allergic agent, antihistaminic, stimulant, sympathomimetic, thyroid agent, vasodilator, PDE IV inhibitor, or a mixture thereof.

17. (Original) The composition according to Claim 1 wherein the drug substance is aspirin, (S)-3-Hydroxy-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide; 6-Acetyl-3,4-dihydro-2,2-dimethyl-trans(+)-4-(4-fluorobenzoylamino)-2H-benzo[b]pyran-3-ol hemihydrate, Rosiglitazone, Carvedilol, Eposartan, hydrochlorthiazide, nifedipine, ketoprofen, indomethacin, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl}propylcarbamate, or a pharmaceutically acceptable salt thereof of any of these agents.

18. (Original) The composition according to Claim 1 in which active agent is present in an amount of about 1 to about 50% w/w.

19. (Original) The composition according to Claim 1 which is intended for oral administration.

20. (Original) The composition according to Claim 1 in which the active agent demonstrates improved bioavailability and/or improved stability, or has a modified or delayed absorption profile as compared to an immediate release dosage form.

21. (Original) The composition according to Claim 1 in which the electrospun fiber is encapsulated or compressed into a tablet or capsule.

22. (Original) The composition according to Claim 1 in which the electrospun fiber is further ground in size.

23. (Original) The composition according to Claim 1 which results in a rapid dissolution of the fiber.

24. (Original) The composition according to Claim 1 which results in controlled release, sustained release, or pulsatile release of the active agent.

25. (Original) The composition according to Claim 1 which results in immediate release of the active agent.

26. (Original) Use of a composition according to Claim 1 for inhalation therapy.

27. (Original) Use of a composition according to Claim 1 for dispersion in an aqueous solution.

28. (Currently amended/withdrawn) A process for making a stable formulation of an amorphous form of a pharmaceutically active agent according to Claim 1 comprising

- a) making a solution of the active agent, and a pharmaceutically acceptable polymeric carrier with a pharmaceutically acceptable solvent; and
- b) electrospinning the solution of step (a) into an electrospun fiber.

29. (Withdrawn) The process according to Claim 28 wherein the solvent is water miscible.

30. (Currently amended/Withdrawn) The process according to Claim 28 wherein the solvent is water [[immiscible]] immiscible.

31. (Withdrawn) The process according to Claim 28 wherein the solution is mixture of one or more solvents.

32. (Withdrawn) The process according to Claim 29 wherein the solvent is a mixture of water and a water miscible solvent.

33. (Withdrawn) The process according to Claim 28 wherein the solvent is ethanol, or a mixture of ethanol and methylene chloride or tetrahydrofuran.

34. (Currently amended/Withdrawn) The process according to Claim 28 wherein the polymeric carrier is polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrrolidone, hyaluronic acid, alginates, carragenen, ~~cellulose derivatives such as~~ carboxymethyl cellulose sodium, ~~methyl cellulose, ethyl cellulose,~~ hydroxyethyl cellulose,

hydroxypropylcellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, ~~noncrystalline cellulose, starch and its derivatives such as~~ hydroxyethyl starch, sodium starch glycolate, ~~chitosan and its derivatives,~~ albumen, gelatin, collagen, polyacrylates and its derivatives, poly(alpha-hydroxy acids), poly(alpha-aminoacids) and its copolymers, poly(orthoesters), polyphosphazenes, or poly(phosphoesters).

35. (Withdrawn) The process according to Claim 34 wherein the polymeric carrier is polyvinyl pyrrolidone, or polyvinylpyrrolidone-co-polyvinylacetate.

36. (Withdrawn) The composition according to claim 34 wherein the polymeric carrier is Eudragit L100-55, Eudragit L30 D55, Eudragit L100, Eudragit S 100, Eudragit E 100, Eudragit EPO, Eudragit RL 30D, Eudragit RL PO, Eudragit RL 100, Eudragit RS 30D, Eudragit RS PO, Eudragit RS 100, Eudragit NE 30, or Eudragit NE 40, or a mixture thereof.

37. (Withdrawn) The process according to Claim 28 wherein the active agent is an analgesic, anti-inflammatory agent, anthelmintic, anti-arrhythmic agent, an antibiotic, anticoagulant, antidepressant, antidiabetic agent, antiepileptic, antihistamine, antihypertensive agent, antimuscarinic agent, antimycobacterial agent, antineoplastic agent, immunosuppressant, antithyroid agent, antiviral agent, anxiolytic sedative, astringent, beta-adrenoceptor blocking agent, contrast media, corticosteroid, cough suppressant, diuretic, dopaminergic, homeostatic, immunological agent, lipid regulating agent, muscle relaxant, parasympathomimetic, parathyroid, calcitonin, prostaglandin, radio-pharmaceutical, sex hormone, steroid, anti-allergic agent, antihistaminic, stimulant, sympathomimetic, thyroid agent, vasodilator, PDE IV inhibitor, or a mixture thereof.

38. (Withdrawn) The composition according to Claim 28 wherein the active agent is aspirin, (S)-3-Hydroxy-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide, or 6-Acetyl-3,4-dihydro-2,2-dimethyl-trans(+)-4-(4-fluorobenzoylamino)-2H-benzo[b]pyran-3-ol hemihydrate, Rosiglitazone, Carvedilol, Eposartan, hydrochlorthiazide, nifedipine, ketoprofen, or indomethacin.

39. (Withdrawn) The product produced by the process according to Claim 28.

40. (Currently amended/Withdrawn) A process for making a stable formulation of an amorphous form of a pharmaceutically active agent according to Claim 1 comprising

a) melting the active agent and a pharmaceutically acceptable polymeric carrier to form a melt; and

b) electrospinning the melt of step (a) into an electrospun fiber.

41. (Currently amended/Withdrawn) The process according to Claim 40 wherein the polymeric carrier is polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrrolidone, hyaluronic acid, alginates, carragenen, ~~cellulose derivatives such as~~ carboxymethyl cellulose sodium, ~~methyl cellulose, ethyl cellulose,~~ hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, ~~noncrystalline cellulose, starch and its derivatives such as~~ hydroxyethyl starch, sodium starch glycolate, ~~chitosan and its derivatives, albumen, gelatin, collagen,~~ polyacrylates and its derivatives, ~~poly(alpha-hydroxy acids),~~ poly(alpha-aminoacids) and its copolymers, poly(orthoesters), polyphosphazenes, or poly(phosphoesters).

42. (Withdrawn) The process according to Claim 41 wherein the polymeric carrier is polyvinyl pyrrolidone, or polyvinylpyrrolidone-co-polyvinylacetate.

43. (Withdrawn) The composition according to Claim 41 wherein the polymeric carrier is wherein the polymeric carrier is Eudragit L100-55, Eudragit L30 D55, Eudragit L100, Eudragit S 100, Eudragit E 100, Eudragit EPO, Eudragit RL 30D, Eudragit RL PO, Eudragit RL 100, Eudragit RS 30D, Eudragit RS PO, Eudragit RS 100, Eudragit NE 30, or Eudragit NE 40, or a mixture thereof.

44. (Withdrawn) The process according to Claim 41 wherein the active agent is an analgesic, anti-inflammatory agent, anthelmintic, anti-arrhythmic agent, an antibiotic, anticoagulant, antidepressant, antidiabetic agent, antiepileptic, antihistamine, antihypertensive agent, antimuscarinic agent, antimycobacterial agent, antineoplastic agent, immunosuppressant, antithyroid agent, antiviral agent, anxiolytic sedative, astringent, beta-adrenoceptor blocking agent, contrast media, corticosteroid, cough suppressant, diuretic, dopaminergic, homeostatic, immunological agent, lipid regulating agent, muscle relaxant, parasympathomimetic, parathyroid, calcitonin, prostaglandin, radio-pharmaceutical, sex hormone, steroid, anti-allergic agent, antihistaminic, stimulant, sympathomimetic, thyroid agent, vasodilator, PDE IV inhibitor, or a mixture thereof.

45. (Withdrawn) The composition according to Claim 41 wherein the active agent is, aspirin, (S)-3-Hydroxy-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide, or 6-Acetyl-3,4-dihydro-2,2-dimethyl-trans(+)-4-(4-fluorobenzoylamino)-2H-benzo[b]pyran-3-ol hemihydrate, Rosiglitazone, Carvedilol, Eposartan, hydrochlorthiazide, nifedipine, ketoprofen or indomethacin.

46. (Withdrawn) The product produced by the process according to Claim 41.